Pulmonary arterial hypertension: Are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?

Rheumatology

Volumn 44, Issue 2, 2005, Pages 141-142

  Black, Carol M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; SEROTONIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; EARLY DIAGNOSIS; EDITORIAL; HEART LUNG TRANSPLANTATION; HEART RIGHT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; LUNG DISEASE; LUNG FUNCTION TEST; MEDICAL DECISION MAKING; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; SCLERODERMA; SCREENING; SURVIVAL; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; PATIENT CARE TEAM; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 14044250268     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh474     Document Type: Editorial

References (14)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25.
2. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123: 344-50.
3. Denton C, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29:335-49.
4. Mukerjee D, St George D, Knight C et al. Prevalence and outcome in systemic sclerosis associated pulmonary hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088-93.
5. Magdiliano M, Isenberg DA, Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases. Arthritis Rheum 2002;46: 1997-2009.
6. Gibbs JSR, Higenbottam T. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86:i1-i13.
7. Rubin LJ, Badesch DB, Barst R et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896-903.
8. Filep JG. Endothelin peptides: biological actions and pathophysiological significance in the lung. Life Sci 1993;52:119-33.
9. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
10. Rubin LJ, Badesch DB, Barst R et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896-903.
11. Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther 2002;7:9-19.
12. McLaughlin V Sitbon O, Rubin LJ et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. American Thoracic Society, 99th International Conference, Seattle, 16-21 May 2003; abstract A442.
13. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
14. Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised trial. Lancet 2002;360:895-900